Results 231 to 240 of about 8,055 (251)

An Introduction to Tirzepatide

Clinical Diabetes, 2022
exaly   +3 more sources

Tirzepatide and prevention of chronic kidney disease [PDF]

CKJ: Clinical Kidney Journal, 2023
Chronic kidney disease; Diabetes mellitus; ObesityMalaltia renal crònica; Diabetis mellitus; ObesitatEnfermedad renal crónica; Diabetes mellitus; ObesidadTirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes ...
Sol María Carriazo Julio, BEATRIZ Fernández-Fernández, Alberto Ortiz Arduan   +2 more
exaly   +2 more sources

Tirzepatide

Hospital Pharmacy, 2022
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Danial E. Baker, Kaitlyn Walley, Terri L. Levien   +2 more
openaire   +2 more sources

Tirzepatide

JAAPA, 2023
ABSTRACT Obesity affects a large percentage of patients in the United States and is associated with increased mortality and higher healthcare costs. Newer guidelines recommend a minimum of 10% weight loss goal for patients with obesity, and medical management options fall short.
Christine G, Niedbala, Roxanne, Sprague
  +5 more sources

Tirzepatide for Lipodystrophy

Abstract Background Lipodystrophy encompasses a group of rare disorders associated with severe metabolic disease. These disorders are defined by abnormal fat distribution, with near-total (generalized lipodystrophy, GL) or partial (partial lipodystrophy, PL; i.e. familial partial lipodystrophy, FPLD)
Rasimcan Meral, Merve Celik Guler, Diarratou Kaba, Jeevitha Prativadi, Eric D Frontera, Maria Cristina Foss-Freitas, Noura Nachawi, David T Broome, Marissa Lightbourne, Rebecca J Brown, Simeon I Taylor, Elif A Oral   +11 more
openaire   +2 more sources

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

Diabetes, Obesity and Metabolism, 2023
Carel Le Roux, Raleigh Malik, Sean Wharton   +2 more
exaly  

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review

Molecules, 2022
Vasso Apostolopoulos, Joanna Bojarska, Vivek Chavda   +2 more
exaly  

Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway

International Immunopharmacology, 2023
Wei Shuai
exaly  

Adverse Events Related to Tirzepatide

Journal of the Endocrine Society, 2023
Lakshmi Kannan, Isain Zapata, Rishi Raj   +2 more
exaly  

Beyond glycemia: Comparing tirzepatide to GLP-1 analogues

Reviews in Endocrine and Metabolic Disorders, 2023
Shawn Smith, John Andraos
exaly